Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3

Next Previous
Trial Profile

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aguracingene cadoparvovec (Primary)
  • Indications Colour vision defects
  • Focus Adverse reactions; First in man; Pharmacogenomic; Therapeutic Use
  • Acronyms CNGA3
  • Sponsors MeiraGTx

    • Most Recent Events

    • 10 Feb 2022 Primary endpoint has changed from Incidence of Adverse Events related to the treatment to Reduction in visual acuity by 15, Early Treatment Diabetic Retinopathy Study (ETDRS) letters or more that fails to resolve to within 15 letters of baseline in a 4-week period once prophylactic treatment commences, Severe unresponsive inflammation, Infective endophthalmitis, Ocular malignancy, Grade III or above non-ocular Suspected Unexpected Serious Adverse Reaction (SUSAR), according to ClinicalTrials.gov
    • 24 Jun 2021 Status changed from recruiting to completed.
    • 11 May 2021 According to MeiraGTx Holdings media release, the company has completed dosing of both adults and pediatric patients in this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top